Nautilus Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Nautilus Biotechnology
NAUT Stock  USD 2.00  0.01  0.50%   
Nautilus Biotechnology financial statements provide useful quarterly and yearly information to potential Nautilus Biotechnology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Nautilus Biotechnology financial statements helps investors assess Nautilus Biotechnology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Nautilus Biotechnology's valuation are summarized below:
Market Capitalization
252.4 M
Earnings Share
(0.56)
There are currently one hundred twenty fundamental ratios for Nautilus Biotechnology that can be evaluated and compared over time across peers in the industry. All traders should check Nautilus Biotechnology's last-minute fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction.
Check Nautilus Biotechnology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nautilus Biotechnology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.6 M, Interest Expense of 7 M or Selling General Administrative of 25.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 2.12. Nautilus financial statements analysis is a perfect complement when working with Nautilus Biotechnology Valuation or Volatility modules.
  
Check out the analysis of Nautilus Biotechnology Correlation against competitors.
For more information on how to buy Nautilus Stock please use our How to Invest in Nautilus Biotechnology guide.

Nautilus Biotechnology Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets239 M351.4 M191.3 M
Slightly volatile
Short and Long Term Debt Total50.6 M31.2 M31.3 M
Pretty Stable
Other Current Liabilities4.8 M4.5 M1.1 M
Slightly volatile
Total Current Liabilities11 M10.5 M2.9 M
Slightly volatile
Cash21.2 M22.3 M25.7 M
Slightly volatile
Non Current Assets Total90.6 M148 M118 M
Slightly volatile
Cash And Short Term Investments148.3 M156.1 M81.3 B
Slightly volatile
Common Stock Total Equity13.1 K13.8 K8.8 M
Pretty Stable
Common Stock Shares Outstanding150.8 M143.7 M45.6 M
Slightly volatile
Short Term Investments131.7 M138.6 M81.3 B
Slightly volatile
Liabilities And Stockholders Equity239 M351.4 M191.3 M
Slightly volatile
Non Current Liabilities Total26.6 M28 M35.9 M
Pretty Stable
Other Stockholder Equity564.9 M538 M156.9 M
Slightly volatile
Total Liabilities48.8 M36.2 M98.6 M
Slightly volatile
Total Current Assets148.4 M203.4 M73.2 M
Slightly volatile
Common Stock15.7 K14.9 K4.4 K
Slightly volatile
Property Plant And Equipment Net23.9 M42.4 M11.6 M
Slightly volatile
Accounts Payable1.2 M1.9 M691.6 K
Slightly volatile
Property Plant Equipment3.7 M4.3 M2.2 M
Slightly volatile
Warrants112.2 M126.2 M137.6 M
Slightly volatile
Capital Surpluse331.9 M523.6 M142 M
Slightly volatile
Capital Lease Obligations27.4 M39.8 M13.4 M
Slightly volatile
Deferred Long Term Liabilities169.6 K190.8 K208 K
Slightly volatile
Property Plant And Equipment Gross50.2 M47.8 M14.3 M
Slightly volatile
Capital Stock10.4 K14.9 K4.6 K
Slightly volatile
Non Current Liabilities Other23 M32.6 M12.4 M
Slightly volatile
Net Working Capital210.7 M192.9 M119.8 M
Slightly volatile
Short Term Debt3 M4.1 M2.1 M
Slightly volatile

Nautilus Biotechnology Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.6 M1.7 M416.1 M
Slightly volatile
Selling General Administrative25.5 M26 M71 M
Slightly volatile
Other Operating Expenses58.2 M87.6 M84.8 M
Slightly volatile
Total Operating Expenses58.2 M87.6 M84.8 M
Slightly volatile
Total Other Income Expense Net10.7 M11.2 M417.8 M
Slightly volatile
Research Development27.5 M52.2 M12.8 M
Slightly volatile
Interest Income15 M14.3 M3 M
Slightly volatile
Cost Of Revenue3.9 M6.6 M3 M
Slightly volatile
Reconciled Depreciation3.8 M5.8 M2.9 M
Slightly volatile
Income Tax Expense3.9 M6.7 M3 M
Slightly volatile
Net Interest Income15 M14.3 M3.2 M
Slightly volatile
Selling And Marketing Expenses3.1 M3.5 M3.8 M
Slightly volatile

Nautilus Biotechnology Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Other Cashflows From Financing Activities314.6 K331.2 K81.7 B
Slightly volatile
Total Cash From Financing Activities314.6 K331.2 K81.7 B
Slightly volatile
End Period Cash Flow22.3 M23.5 M26 M
Slightly volatile
Stock Based Compensation14.7 M14 M3.8 M
Slightly volatile
Begin Period Cash Flow98.7 M103.9 M782.8 M
Slightly volatile
Depreciation6.9 M6.6 M2.1 M
Slightly volatile
Dividends Paid42.4 K47.7 K52 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Capex To Depreciation0.880.491.2854
Slightly volatile
Payables Turnover3.524.04.3901
Slightly volatile
Cash Per Share1.521.611.3 K
Slightly volatile
Days Payables Outstanding10794.3891.7406
Slightly volatile
Current Ratio21.1822.29163
Slightly volatile
Graham Number10.745.6823.1556
Slightly volatile
Capex Per Share0.02140.02250.0893
Slightly volatile
Interest Debt Per Share0.30.322.889
Very volatile
Debt To Assets0.120.130.9826
Very volatile
Days Of Payables Outstanding10794.3891.7406
Slightly volatile
Long Term Debt To Capitalization0.580.840.6632
Slightly volatile
Quick Ratio21.1822.29163
Slightly volatile
Net Income Per E B T0.880.991.0797
Slightly volatile
Cash Ratio2.322.45139
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.171.21.0969
Pretty Stable
Debt Ratio0.120.130.9826
Very volatile

Nautilus Fundamental Market Drivers

Cash And Short Term Investments173.4 M

Nautilus Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
7th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Nautilus Biotechnology Financial Statements

Nautilus Biotechnology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Nautilus Biotechnology investors may analyze each financial statement separately, they are all interrelated. The changes in Nautilus Biotechnology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Nautilus Biotechnology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-853.2 K-810.5 K
Cost Of Revenue6.6 M3.9 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY